Allovir Stock Net Income
| ALVR Stock | USD 0.55 0.02 3.51% |
Allovir fundamentals help investors to digest information that contributes to Allovir's financial success or failures. It also enables traders to predict the movement of Allovir Stock. The fundamental analysis module provides a way to measure Allovir's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Allovir stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -168.9 M | -160.4 M | |
| Net Loss | -151.8 M | -144.2 M | |
| Net Loss | -190.4 M | -180.9 M | |
| Net Loss | (1.83) | (1.92) | |
| Net Income Per E B T | 1.00 | 0.78 |
Allovir | Net Income |
Allovir Company Net Income Analysis
Allovir's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Allovir Net Income | (190.42 M) |
Most of Allovir's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Allovir is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Allovir Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Allovir is extremely important. It helps to project a fair market value of Allovir Stock properly, considering its historical fundamentals such as Net Income. Since Allovir's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Allovir's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Allovir's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Allovir Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Allovir reported net income of (190.42 Million). This is 155.79% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 133.35% higher than that of the company.
Allovir Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Allovir's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Allovir could also be used in its relative valuation, which is a method of valuing Allovir by comparing valuation metrics of similar companies.Allovir is currently under evaluation in net income category among its peers.
Allovir Current Valuation Drivers
We derive many important indicators used in calculating different scores of Allovir from analyzing Allovir's financial statements. These drivers represent accounts that assess Allovir's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Allovir's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.7B | 1.0B | 812.4M | 393.2M | 70.7M | 67.2M | |
| Enterprise Value | 1.6B | 920.0M | 640.8M | 322.5M | 8.0M | 7.6M |
Allovir Institutional Holders
Institutional Holdings refers to the ownership stake in Allovir that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Allovir's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Allovir's value.| Shares | Geode Capital Management, Llc | 2024-09-30 | 585.5 K | Rbf Llc | 2024-06-30 | 449 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 324.7 K | Fmr Inc | 2024-09-30 | 310.6 K | D. E. Shaw & Co Lp | 2024-09-30 | 296.5 K | Two Sigma Investments Llc | 2024-09-30 | 295.2 K | Goldman Sachs Group Inc | 2024-06-30 | 288 K | State Street Corp | 2024-06-30 | 222.4 K | Commonwealth Equity Services Inc | 2024-06-30 | 201 K | Ecor1 Capital, Llc | 2024-09-30 | 11.3 M | Octagon Capital Advisors Lp | 2024-09-30 | 11.2 M |
Allovir Fundamentals
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | (58.32 M) | ||||
| Shares Outstanding | 115.36 M | ||||
| Shares Owned By Insiders | 49.11 % | ||||
| Shares Owned By Institutions | 42.94 % | ||||
| Number Of Shares Shorted | 3.95 M | ||||
| Price To Book | 0.52 X | ||||
| Gross Profit | 165 K | ||||
| EBITDA | (190.15 M) | ||||
| Net Income | (190.42 M) | ||||
| Cash And Equivalents | 172.67 M | ||||
| Cash Per Share | 1.91 X | ||||
| Total Debt | 27.43 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 8.18 X | ||||
| Book Value Per Share | 1.05 X | ||||
| Cash Flow From Operations | (124.45 M) | ||||
| Short Ratio | 26.44 X | ||||
| Earnings Per Share | (0.90) X | ||||
| Price To Earnings To Growth | (0.06) X | ||||
| Target Price | 1.2 | ||||
| Beta | 0.74 | ||||
| Market Capitalization | 85.25 M | ||||
| Total Asset | 190.8 M | ||||
| Retained Earnings | (656.19 M) | ||||
| Working Capital | 159.27 M | ||||
| Current Asset | 61.62 M | ||||
| Current Liabilities | 53.23 M | ||||
| Net Asset | 190.8 M |
About Allovir Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Allovir's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Allovir using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Allovir based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Allovir
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allovir position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will appreciate offsetting losses from the drop in the long position's value.Moving against Allovir Stock
The ability to find closely correlated positions to Allovir could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allovir when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allovir - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allovir to buy it.
The correlation of Allovir is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allovir moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allovir moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allovir can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Allovir Stock Analysis
When running Allovir's price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.